{
  "report_rows": [
    {
      "kpi": "Revenue",
      "prediction": "BEAT",
      "answer": "pred ~$3.02B vs. cons $2.97B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Non-GAAP EPS",
      "prediction": "BEAT",
      "answer": "pred ~$2.68 vs. cons $2.55",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Worldwide da Vinci procedure growth",
      "prediction": "BEAT",
      "answer": "pred ~15.8% vs. cons 14.5%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 worldwide da Vinci procedure-growth outlook",
      "prediction": "BETTER",
      "answer": "guide ~14.8% midpoint vs. cons 14.5% midpoint (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 non-GAAP gross-margin outlook",
      "prediction": "UNCHANGED",
      "answer": "guide ~68.0% midpoint vs. cons 68.0% midpoint (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 non-GAAP operating-expense-growth outlook",
      "prediction": "UNCHANGED",
      "answer": "guide ~12.5% midpoint vs. cons 12.5% midpoint (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 5.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 7.0,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "Revenue/EPS revisions should move ~2%/~3% higher over the next five days as a ~15.8% procedure print and a ~14.8% FY2026 procedure-guide midpoint support out-period recurring-revenue and dV5 monetization assumptions.",
  "day5_confidence": "MEDIUM"
}